Author | f/u* (mo’s) | Treatment | n | Breast Failure (%) | Cosmesis | ||
|
|
|
| Total | True** | Elsewhere | Good Excellent |
Formenti S [89] NYU | >36 | Prone *25 - 30 Gy 5 fx 10 days, | 10 | 0% | 0% | 0% | 100% |
Taghian [95] Harvard | N.S. | *32 Gy 4 Gy bid × 8 | 61 | N.S. | |||
Vicini et al. [96] William Beaumont | 24 | *34 or 38.5 Gy in 10 bid fx | 91 | 0% | 0% | 0% | 90% |
Vicini et al. [107] William Beaumont | 10 | *Supine *38.5 Gy ? 3.85 Gy bid × 10 | 31 | 0% | 0% | 0% | 100% |
Pashtan [108] | 71 | *32 Gy ? 4Gy bid fx 8 | 98 | 5% | 5% | 0% | N.S. |
Lei et al. [65] Institutional Review Board | 60 | **38.5 Gy - 3.85 bid fx | 136 | <1% | 0% | <1% | 90.5% |
Bergom et al. [103] | 20 | **38.5 Gy - 3.85 bid fx | 19 | 0% | 0% | 0% | 95% |
Polgar [104] | 122 | WBI 50 Gy | 130 | 4.6% | - | - | 63%
|
PBI HDR 7 × 5.2 Gy |
|
|
|
|
| ||
or EB 50 Gy | 128 | 5.5% |
|
| 81% | ||
Livi [105] U. Florence | 60 | WBI 50 Gy/25 F with 10 Gy boosts/5 F | 260 | 1.4% | 1.9% | 0% | 99.2% |
IMRT 30 Gy/5 F | 260 | 1.5% | 1.5% | 1.5% | 100% | ||
Coles [106] IMPORT LOW | 68.3 | WBI 40 Gy/15 F | 675 | 1.1% | - | - | - |
WBI 36 Gy/15 F and | 674 | 0.2% | - | - | - | ||
APBI 40 Gy/15 F |
|
|
|
|
| ||
APBI 40 Gy/15 F | 669 | 0.5% | - | - | - |